Priming Innovative Translational Research - the Glasgow Chemical Biology Programme
Lead Research Organisation:
University of Glasgow
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Baillie GS
(2019)
Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.
in Nature reviews. Drug discovery
Blair CM
(2019)
Reshaping cAMP nanodomains through targeted disruption of compartmentalised phosphodiesterase signalosomes.
in Biochemical Society transactions
Blair CM
(2019)
Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
in BMC cancer
Carini C
(2018)
Chromosome conformation signatures define predictive markers of inadequate response to methotrexate in early rheumatoid arthritis.
in Journal of translational medicine
Carpena N
(2021)
Targeted Delivery of Narrow-Spectrum Protein Antibiotics to the Lower Gastrointestinal Tract in a Murine Model of Escherichia coli Colonization.
in Frontiers in microbiology
Kelleher J
(2019)
Patient-Specific iPSC Model of a Genetic Vascular Dementia Syndrome Reveals Failure of Mural Cells to Stabilize Capillary Structures.
in Stem cell reports
Moreton FC
(2018)
Vasoreactivity in CADASIL: Comparison to structural MRI and neuropsychology.
in Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
Neves KB
(2019)
ER stress and Rho kinase activation underlie the vasculopathy of CADASIL.
in JCI insight
Tibbo AJ
(2019)
Understanding PDE4's function in Alzheimer's disease; a target for novel therapeutic approaches.
in Biochemical Society transactions
| Description | High-Growth Spinout Programme |
| Amount | £394,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2017 |
| End | 11/2018 |
| Description | BioClavis |
| Organisation | BioSpyder Technologies Inc |
| Country | United States |
| Sector | Private |
| PI Contribution | Using clinical samples obtained in the ORBIT trail, the research team generated the initial bioinformatic signatures (from RNAseq data) that were able to stratify rheumatoid arthritis patients into responders and non-responders to biological therapies. This enable the research team to create a new gene list for testing in the BioSpyder TempO-seq platform. |
| Collaborator Contribution | BioSpyder have been able to work in parallel with the research team to design an appropriate TempO-seq assay. The rationale for this is that to translate our initial bioinformatic signatures into a useful clinical test requires us to use a assay that has the potential to be used in the clinic. The TempO-seq assay has this potential. |
| Impact | No output or outcomes to date, as the study is still on-going. |
| Start Year | 2017 |
| Title | ???????????????????? |
| Description | The invention relates to the treatment of bacterial respiratory infections using the bacterially-originating antibiotics known as pyocins. In particular, the invention provides the use of S-type pyocins, administered by pulmonary administration, for the treatment of such infections. |
| IP Reference | CN107073073 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | In development |
| Title | ?????????????????????????? |
| Description | ?????????????????????????????????????????????????????????????????????????????????S?????????????????????? |
| IP Reference | JP2017529398 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | In development |
| Title | NANOSTRUCTURED SURFACES |
| Description | A method of forming nanostructures on a curved surface of a substrate, such as a metallic medical implant, is disclosed. A conformable template is provided, having template nanostructures. A sol-gel comprising a patterning precursor is applied to the curved surface with the sol-gel interposed between the conformable template and the curved substrate. In this way, a patterned coating of patterning precursor on the curved substrate is formed. Next, a thermal treatment of the patterned coating is carried out in order to develop the nanostructures. |
| IP Reference | GB20150022690 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | Commercial In Confidence |
| Impact | In development. |
| Title | NANOSTRUCTURED SURFACES |
| Description | A method of forming nanostructures on a curved surface of a substrate, such as a metallic medical implant, is disclosed. A conformable template is provided, having template nanostructures. A sol-gel comprising a patterning precursor is applied to the curved surface with the sol-gel interposed between the conformable template and the curved substrate. In this way, a patterned coating of patterning precursor on the curved substrate is formed. Next, a thermal treatment of the patterned coating is carried out in order to develop the nanostructures. |
| IP Reference | WO2017109002 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | Commercial In Confidence |
| Impact | In development |
| Title | PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY INFECTIONS |
| Description | The invention relates to the treatment of bacterial respiratory infections using the bacterially-originating antibiotics known as pyocins. In particular, the invention provides the use of S-type pyocins, administered by pulmonary administration, for the treatment of such infections. |
| IP Reference | CA2962117 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | In development |
| Title | PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY INFECTIONS |
| Description | The invention relates to the treatment of bacterial respiratory infections using the bacterially-originating antibiotics known as pyocins. In particular, the invention provides the use of S-type pyocins, administered by pulmonary administration, for the treatment of such infections. |
| IP Reference | US2017240602 |
| Protection | Patent application published |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | In development |
| Title | PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY INFECTIONS |
| Description | The invention relates to the treatment of bacterial respiratory infections using the bacterially-originating antibiotics known as pyocins. In particular, the invention provides the use of S-type pyocins, administered by pulmonary administration, for the treatment of such infections. |
| IP Reference | WO2016046218 |
| Protection | Patent application published |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | In development |
| Title | PULMONARY ADMINISTRATION OF PYOCINS FOR TREATING BACTERIAL RESPIRATORY INFECTIONS |
| Description | The invention relates to the treatment of bacterial respiratory infections using the bacterially-originating antibiotics known as pyocins. In particular, the invention provides the use of S-type pyocins, administered by pulmonary administration, for the treatment of such infections. |
| IP Reference | EP3200813 |
| Protection | Patent granted |
| Year Protection Granted | 2017 |
| Licensed | No |
| Impact | In development |
| Title | Pulmonary Administration of Pyocins for Treating Bacterial Respiratory Infections |
| Description | The invention relates to the treatment of bacterial respiratory infections using the bacterially-originating antibiotics known as pyocins. In particular, the invention provides the use of S-type pyocins, administered by pulmonary administration, for the treatment of such infections. |
| IP Reference | GB201416788A |
| Protection | Patent application published |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | In development |
| Company Name | PROTOBIOTIX LIMITED |
| Description | for development of novel therapeutics |
| Year Established | 2018 |
| Impact | none yet |